Friday, 16 October 2026European Markets

OENEO And REMY COINTREAU Have A High Dividend Yield And Return On Equity In The Beverages - Wineries & Distilleries Industry.

Loading stream...

(vianews) - oeneo (sbt.pa) is among this list of stock assets with the highest dividend rate and return on equity on the beverages - wineries & distilleries industry.

financial asset price forward dividend yield return on equity
oeneo (sbt.pa) €11.75 2.92% 10.68%
remy cointreau (rco.pa) €96.10 1.98% 10.38%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. oeneo (sbt.pa)

2.92% forward dividend yield and 10.68% return on equity

oeneo sa operates in the wine industry worldwide. the company manufactures and sale of cork closures. it also provides products and solutions in wine making and spirits. oeneo sa is headquartered in bordeaux, france. oeneo sa operates as a subsidiary of caspar sas.

earnings per share

as for profitability, oeneo has a trailing twelve months eps of €0.52.

pe ratio

oeneo has a trailing twelve months price to earnings ratio of 22.6. meaning, the purchaser of the share is investing €22.6 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.68%.

yearly top and bottom value

oeneo's stock is valued at €11.75 at 21:40 est, way below its 52-week high of €15.55 and higher than its 52-week low of €11.30.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, oeneo's stock is considered to be oversold (<=20).

dividend yield

according to morningstar, inc., the next dividend payment is on oct 3, 2023, the estimated forward annual dividend rate is 0.35 and the estimated forward annual dividend yield is 2.92%.

more news about oeneo.

2. remy cointreau (rco.pa)

1.98% forward dividend yield and 10.38% return on equity

rémy cointreau sa, together with its subsidiaries, engages in the production, sale, and distribution of liqueurs and spirits. the company operates through rémy martin, liqueurs & spirits, and partner brands segments. it offers liqueurs, brandy, gin, single malt whisky, rum, wine, and champagne primarily under the cointreau, metaxa, st-rémy, mount gay, bruichladdich, port charlotte, octomore, the botanist, westland, louis xiii, and domaine des hautes glaces brands. the company operates in europe, the middle east, africa, the americas, asia, australia, and new zealand. rémy cointreau sa was founded in 1724 and is headquartered in cognac, france.

earnings per share

as for profitability, remy cointreau has a trailing twelve months eps of €3.6.

pe ratio

remy cointreau has a trailing twelve months price to earnings ratio of 26.69. meaning, the purchaser of the share is investing €26.69 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.38%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, remy cointreau's stock is considered to be overbought (>=80).

moving average

remy cointreau's worth is under its 50-day moving average of €105.00 and way below its 200-day moving average of €130.91.

more news about remy cointreau.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com